Contineum Therapeutics (CTNM) stake at 2.8% in Millennium 13G/A update

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. has an amended Schedule 13G reporting that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 931,709 shares of Class A common stock. This represents 2.8% of the class.

The shares are reported with shared voting and shared dispositive power and no sole voting or dispositive power. The securities are held by entities over which Millennium Management LLC and related investment managers exercise voting control and investment discretion, with Millennium Group Management LLC as managing member and Mr. Englander as sole voting trustee of its managing member. The filers state that this structure should not by itself be construed as an admission of beneficial ownership. They also indicate that they hold 5 percent or less of the class.

Key Figures

Shares beneficially owned: 931,709 shares Percent of class: 2.8% Shared voting power: 931,709 shares +2 more

5 metrics

Shares beneficially owned 931,709 shares Class A Common Stock reported by Millennium-related filers

Percent of class 2.8% Ownership percentage of CTNM Class A common stock

Shared voting power 931,709 shares Shares over which filers have shared power to vote

Shared dispositive power 931,709 shares Shares over which filers have shared power to dispose

Filing date 07/16/2026 Date of signatures on the Schedule 13G/A amendment

Key Terms

Schedule 13G/A, beneficially owned, shared voting power, dispositive power, +1 more

5 terms

Schedule 13G/A regulatory

"Exhibit I: Joint Filing Agreement, dated as of July 16, 2026"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: See response to Item 9 on each cover page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 931,709.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power financial

"Shared Dispositive Power 931,709.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Joint Filing Agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of July 16, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/17/2026 - 05:11 PM Accepted by SEC EDGAR 07/17/2026 - 05:10 PM Learn about SEC filing dates

FAQ

What ownership stake in CTNM does Millennium report in this Schedule 13G/A amendment?

Millennium and related reporting persons report beneficial ownership of 931,709 shares of Contineum Therapeutics Class A common stock, representing 2.8% of the class, held with shared voting and shared dispositive power through affiliated investment entities.

Who are the reporting persons on the CTNM Schedule 13G/A amendment?

The Schedule 13G/A for CTNM lists Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander as reporting persons, reflecting their control relationships over investment entities holding Contineum Therapeutics Class A common stock.

How much voting power do the Millennium entities report over CTNM shares?

The reporting persons disclose 0 shares with sole voting power and 931,709 shares with shared voting power in CTNM. They also report the same 931,709 shares with shared dispositive power and no sole dispositive power.

Does Millennium’s reported CTNM stake exceed 5% of the class?

No. The Schedule 13G/A specifies that the reporting persons’ ownership is 2.8% of the class of CTNM Class A common stock and is disclosed under the item for ownership of 5 percent or less of a class.

How do Millennium and Israel A. Englander describe their beneficial ownership of CTNM?

They state that CTNM securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and other managers, and that this structure should not be construed as an admission of beneficial ownership by the reporting persons.

What joint agreement is associated with the CTNM Schedule 13G/A filing?

The filing includes an exhibit titled Joint Filing Agreement, dated July 16, 2026, among Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, confirming their agreement to make a joint filing regarding their CTNM holdings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Contineum Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

21217B100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 21217B100

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 931,709.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 931,709.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

931,709.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 21217B100

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 931,709.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 931,709.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

931,709.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 21217B100

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 931,709.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 931,709.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

931,709.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Contineum Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3565 General Atomics Court, Suite 200, San Diego, California 92121
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Class A Common Stock, par value $0.001 per share
(e)	CUSIP No.: 21217B100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/16/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/16/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	07/16/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of July 16, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.